Research in contextEvidence before this studyMounting evidence demonstrated that immune systems interact with tumour cells and crucially influence multiple tumour processes. Tumour-infiltrating lymphocytes (TILs) have been demonstrated to reflect tumour inflammation and to correlate with prognostic outcomes in tumours. We searched PubMed for studies published in English reporting the prognostic effect of tumour-infiltrating lymphocytes in GISTs. The following terms were used as search terms: "gastrointestinal stromal tumors" or "GISTs", "tumour-infiltrating lymphocytes" or "lymphocytes". Twelve studies were identified. TILs were reported to be important in GISTs, but the prognostic role has not yet been clearly elucidatedAdded value of this studyThe prognostic discrimination capability of the II-GIST signature, integrating the CD3^+^ TC, CD3^+^ TM, CD8^+^ TM and CD45RO^+^ TM, was significantly superior to that of the NIH risk criteria. Moderate- and high-risk patients with high II-GIST scores might obtain a greater survival benefit from postoperative imatinib therapy compared with those with low II-GIST scores.Implications of all the available evidenceThe current study indicated that the II-GIST signature based on immune infiltrations can effectively individualize prognostic predictions for GIST patients and serve as a useful predictor of the response to imatinib. Identifying and understanding additional immune abnormalities in GISTs may offer significant implications for future risk stratification and therapeutic opportunities.Alt-text: Unlabelled box

1. Introduction {#sec0004}
===============

Gastrointestinal stromal tumours (GISTs), first proposed by Mazur in 1983, have often been diagnosed as smooth muscle tumours or schwannomas due to the incomplete understanding of their origin and differentiation \[[@bib0001], [@bib0002]\]. With the development of molecular diagnostic approaches, GISTs have become the most frequently diagnosed mesenchymal malignancy of the gastrointestinal (GI) tract [@bib0003]. The US National Institutes of Health (NIH) risk criteria, the most commonly used staging system for GISTs, provide useful but insufficient information to predict prognosis. Therefore, interest in identifying new parameters to improve the predictive accuracy of the current GIST staging system is increasing.

Emerging evidence suggests that immune systems interact with tumour cells and crucially influence multiple tumour processes, such as progression and metastasis [@bib0004]. Recent reports have demonstrated that infiltration of immune cells, especially lymphocytes, is critically important in tumours and is a primary determinant of survival outcomes in various types of cancers, including colon, ovarian, lung, gastric and breast cancers [@bib0005], [@bib0006], [@bib0007], [@bib0008]. There has been considerable progress in understanding the role of patients' pre-existing tumour-specific immunity---especially that related to tumour-infiltrating lymphocytes (TILs), which act as prognostic biomarkers in tumour progression \[[@bib0009], [@bib0010]\]. Tumour levels of CD3^+^lymphocytes have been demonstrated to be independent prognostic indicators [@bib0011]. CD8^+^cytotoxic T lymphocytes (CTLs), key components of the immune system, can potently target and eliminate tumour cells and are correlated with favourable survival outcomes [@bib0012]. CD45, a transmembrane phosphatase, regulates cytokine signalling and various corresponding biological processes, including cell proliferation, differentiation and activation [@bib0013]. Accumulating evidence suggests that patients with tumours that have high CD45RO^+^ *T* cell densities have less tumour invasiveness and better survival outcomes [@bib0014]. A meta-analysis performed in breast cancer demonstrated that TILs are predictors of a favourable response to chemotherapy [@bib0015]. With respect to GISTs, Rusakiewicz et al. demonstrated that infiltrations of CD3^+^ and NKp46^+^ cells are associated with a reduced relapse rate in the 54 GIST patients using immunohistochemistry (IHC) [@bib0016]. Vitiello et al. indicated that compared with KIT-mutant GIST, the infiltrations of CD45RO^+^ and CD8^+^ cells are higher in PDGFRA-mutant GISTs by IHC, which comparatively tend to be resistant to imatinib [@bib0017]. Balachandran et al. reposted that inhibition of oncogenic KIT in tumour cells promoted the apoptosis of regulatory Foxp3^+^ *T* cells and CD4^+^ TILs are diffusely infiltrated in GISTs [@bib0018]. However, the prognostic role of these TILs has not yet been clearly elucidated. Although seldom been reported in GIST, CD20 expressing on the surface of all B-cells, which are an important type of lymphocyte, has also been selected as a B-lymphocyte antigen. Hence, the current study sought to investigate the prognostic impact of CD3^+^, CD8^+^, CD45RO^+^, Foxp3^+^, CD4^+^, NKp46^+^ and CD20^+^ TILs in GISTs.

Considering the complexity of immune components, individual evaluation of each type of TILs might show only moderate predictive accuracy. Thus, an immune signature comprising multiple types of TILs might notably increase the precision of prognostic estimates. For instance, an immunoscore summarizing the distribution of CD3^+^ and CD8^+^TIL effectors in both the centre and invasive margin of the tumour has been demonstrated to be a reliable model for discriminating prognostic outcomes in colorectal cancer [@bib0007]. A recent study demonstrated that a 5-feature-based immunoscore signature was efficacious enough to estimate recurrence risk and predict chemosensitivity in gastric cancer [@bib0005]. Thus, we sought to investigate the distribution and density of TILs and to develop an immune infiltration (II)-based signature to predict prognosis and the efficacy of adjuvant imatinib therapy in patients with GIST.

2. Methods {#sec0005}
==========

2.1. Ethics statement {#sec0006}
---------------------

This study was approved by the Ethical Review Committee of the First Affiliated Hospital of Sun Yat-sen University and the Second Affiliated Hospital of Guangzhou University of Chinese Medicine. All patients in this study signed an informed consent form.

2.2. Patients and tissue samples {#sec0007}
--------------------------------

We retrospectively retrieved GIST patient information from the prospectively established database at the First Affiliated Hospital of Sun Yat-sen University and the Second Affiliated Hospital of Guangzhou University of Chinese Medicine. The inclusion criteria were as follows: (1) histologically proven GIST; (2) available archived samples with tumour components and margins; (3) lack of preoperative systemic treatment; (4) absence of synchronous or metachronous cancers; and (5) complete clinicopathological and follow-up information. Finally, 435 eligible formalin-fixed paraffin-embedded specimens that were collected between 2005 and 2015 were used for the current study. We randomly assigned GIST patients from the First Affiliated Hospital of Sun Yat-sen University to the training (*n* = 130) and internal validation (*n* = 194) cohorts. Another 111 patients from the Second Affiliated Hospital of Guangzhou University of Chinese Medicine were enrolled into the external validation cohort. Moderate-risk and high-risk patients who received imatinib were previously analysed for mutations and were identified as having sensitive mutations according to the guidelines [@bib0019].

2.3. Assessment of TILs, PD-1 and PD-L1 {#sec0008}
---------------------------------------

IHC was performed as previously described [@bib0020]. Briefly, tissue sections (4--5 μm in thickness) were deparaffinized and rehydrated. Tissue slides were subjected to antigen retrieval by microwave heating in 10 mM citrate buffer (pH 6.0) and were quickly immersed in 3% H~2~O~2~ to quench endogenous peroxidase activity. Then, sections were incubated with primary antibodies against CD3 (Ventana, 790--4341; ready-to-use), CD8 (Dako, M7103; 1:100 dilution), CD45RO (Origene, TA807197; 1:100 dilution), CD4 (Abcam, ab213215; 1:300 dilution), Foxp3 (Abcam, ab22510; 1:200 dilution), NKp46 (Abcam, ab214468; 1:500 dilution), CD20 (Abcam, ab27093; 1:200 dilution), programmed death-1(PD-1) (Cell signaling Technology, 43,248; 1:50 dilution), and programmed death-ligand 1 (PD-L1) (Dako, M3653; 1:50 dilution) at 4 °C overnight.

The density and distribution of CD3^+^, CD8^+^, CD45RO^+^, Foxp3^+^, CD4^+^, NKp46^+^, CD20^+^ and PD-1^+^TILs in the samples were assessed in two specific areas: the tumour centre (TC) and tumour margin (TM). The TM is defined as a region 800 µm wide centred on the border of the malignant cells with the fibrous trabeculae, and the TC is defined as the central tumour tissue surrounded by the TM (Fig. S1). Two pathologists (Lu XF and Ding L), who were blinded to the clinicopathological features, reviewed the stained slides to determine the TC and TM regions. Each pathologist independently selected 5 high-power fields (at 200 × magnification) in each region to assess the density of stained immune cells. ImageJ was used to calculate the absolute counts of TILs according to the operating parameters established by the two pathologists [@bib0021]. If scores were obviously different or if the infiltration was heterogeneous, the two pathologists worked collaboratively to provide a result. If major discrepancies still existed, a third pathologist (Professor Xue L) assessed the samples and collaborated with the other two to provide a final result. The cases of major discrepancy between the two pathologists in review were 188 (2.4%). The optimum density threshold for each feature was determined with the R package "Maxstat," as previously described [@bib0022].

Staining intensity of PD-L1 was graded as negative, weak, moderate, or strong. Samples with 10% of tumour cells exhibiting moderate to strong staining intensity for PD-L1 were deemed as positive.

2.4. Construction of the II-based signature {#sec0009}
-------------------------------------------

Considering the comparatively limited number of events in the training cohort relative to the number of variables and avoiding over-fitting due to the high dimensionality of the immune-infiltration-based signature, the least absolute shrinkage and selection operator (LASSO) was utilized to select significant features and obtain an optimal model. LASSO is a robust method that can be used with high-dimensional data for optimal selection of factors with strong diagnostic or prognostic value \[[@bib0023], [@bib0024]\]. LASSO shrinks the absolute size of coefficient estimates towards exactly zero depending on a penalized factor called λ, and thereby minimizes the prediction error. Briefly, as the value of λ increases, the coefficients of predictors in LASSO decrease (even to zero), which is pivotal for the establishment of a low-dimensional model with interpretability. In order to avoid over-fitting, 10-time cross-validation was used to determine the coefficients of LASSO modelling. Meanwhile, the mean-squared error should be as small as possible to improve the prediction accuracy. If λ with minimal partial likelihood deviance was used, 10 features would be chosen, which might led to over-fitting. Hence, 1-SE criteria was used to select lambda (λ=0.0634) for further analysis. Here, a value λ= 0.0634 with log(λ)= −2.759 was determined by 10-time cross-validation *via* 1-SE criteria in our study. Four parameters (CD3^+^ TC, CD3^+^TM, CD8^+^ TM and CD45RO^+^ TM) were finally included in the II-based signature in the training cohort ([Fig. 1](#fig0001){ref-type="fig"}). The II-GIST score was calculated as follows: (0.0000019123 × CD3^+^ TC count) + (0.0000559617 × CD3^+^ TM count) + (0.0028924318 × CD8^+^ TM count) + (0.0007187206 × CD45RO^+^ TM count). The R package "glmnet" was used for the LASSO Cox regression analysis [@bib0025]. We used maximally selected rank statistics to define the threshold value for II-GIST as 0.58 in order to divide patients into the high II-GIST and low II-GIST groups. According to the above formula, high expression was defined as 1, and low expression was defined as 0.Fig. 1Construction of the II-GIST signature comprising 4 immune features. (a) Tenfold cross validation for tuning parameter selection in the LASSO model. The solid vertical lines represent partial likelihood deviance ± standard error (SE) values. The dotted vertical lines are drawn at the optimal values according to the minimum criteria and 1-SE criteria. Here, a value of λ= 0.0634 with log(λ)= −2.759 was selected by 10-fold cross validation with the 1-SE criteria. (b) LASSO coefficient profiles of the GIST-associated immune features.Fig. 1

2.5. Statistical analysis {#sec0010}
-------------------------

For categorical variables, the associations between the TIL densities and the clinicopathological features were analysed *via* the χ^2^ test or Fisher\'s exact test. For continuous variables, parametric or nonparametric tests were used to compare the differences between groups.

Survival curves were calculated by the Kaplan-Meier method and were compared by log-rank tests. We conducted univariate analysis to investigate the associations between clinicopathological features and survival outcomes. Variables with *P*\< 0.25 in the univariate analysis were incorporated into a multivariable analysis that employed a Cox proportional hazards model using the backward method. The Cox model was also used to investigate the interactions between the II-GIST signature and adjuvant imatinib therapy. The time-dependant area under the receiver operating characteristic (ROC) curve (AUC) was calculated to compare the prognostic discrimination capability of each immune infiltration and the prediction models for GISTs. In addition, Harrell\'s concordance index (C-index) with 95% confidence interval (CI) was calculated to evaluate discrimination by the II-GIST signature and the NIH risk criteria. The relative importance of each parameter to survival risk was assessed using the χ2 statistics by R package "rms" [@bib0026]. All statistical analyses were performed with SPSS (Inc., Chicago, IL, USA) and R software.

3. Results {#sec0011}
==========

3.1. Density and distribution of TILs in GISTs {#sec0012}
----------------------------------------------

Initially, CD3^+^, CD8^+^, CD45RO^+^, Foxp3^+^, CD4^+^, NKp46^+^ and CD20^+^ cells were evaluated separately in the TC and TM (Fig. S2). More CD3^+^, CD8^+^, CD4^+^ and NKp46^+^cells were detected in the TM than in the TC (Fig. S3a, b, e and f). The densities of CD45RO^+^, Foxp3^+^ and CD20^+^ cells were similar between the TC and TM (Fig. S3c, d and g).

Then, we analysed the associations between the clinicopathological variables and the absolute counts of CD3^+^, CD8^+^, CD45RO^+^, Foxp3^+^, CD4^+^, NKp46^+^ and CD20^+^ cells in the TC and TM. Localized GISTs exhibited higher CD8^+^ (Wilcoxon Rank Sum test, *P* = 0.008) and Foxp3^+^ (Wilcoxon Rank Sum test, *P*\<0.001) cell densities in the TM compared with metastatic GISTs (Fig. S4b and d). The CD45RO^+^ cell counts in the TC were higher in tumours ≤5 cm in size than in tumours \>5 cm in size (Wilcoxon Rank Sum test, *P* = 0.023) (Fig. S5c). Stomach GISTs exhibited a lower prevalence of CD8^+^ cells in both the TC (Wilcoxon Rank Sum test, *P* = 0.001) and TM (Wilcoxon Rank Sum test, *P* = 0.001) than non-gastric GISTs (Fig. S6b).

Next, we investigated associations between the density of TILs in the TC or TM and the prognosis of GIST patients. The Kaplan-Meier analysis results suggested that high levels of CD3^+^, CD8^+^, CD45RO^+^, NKp46^+^ and CD20^+^ cell infiltration in both the TC and TM correlated with improved recurrence-free survival (RFS) and overall survival (OS) outcomes ([Fig. 2](#fig0002){ref-type="fig"} and Fig. S7--9). The time-dependant ROC curve analysis revealed the prognostic discrimination capability of individual TILs (Fig. S10 and Table S1--2). Multivariable Cox proportional regression analyses after adjustment for other clinicopathological variables demonstrated that high levels of CD3^+^ TC, CD3^+^ TM, CD8^+^ TC, CD8^+^ TM, CD45RO^+^ TM, NKp46^+^ TM and CD20^+^ TM infiltrations were independent prognostic factors for GIST outcomes (Table S3). In addition, moderate correlations were detected in pairs (TC and TM) of CD3^+^, CD8^+^, CD45RO^+^, CD20^+^ and NKp46^+^ TILs, as shown in Figure S11.Fig. 2Kaplan-Meier analysis of RFS according to individual TIL populations in the TC. (a) CD3^+^ TC. (b) CD8^+^ TC. (c) CD45RO^+^ TC. (d) Foxp3^+^ TC. (e) CD4^+^ TC. (f) NKp46^+^ TC. (g) CD20^+^ TC.Fig. 2

3.2. II-GIST signature and survival of GIST patients {#sec0013}
----------------------------------------------------

The baseline characteristics of the training, internal validation and external validation cohorts are listed in [Table 1](#tbl0001){ref-type="table"}. First, we developed a prediction model using a LASSO Cox regression model based on the training cohort, which ultimately included 4 immune features ([Fig. 1](#fig0001){ref-type="fig"}).Table 1Clinical characteristics of patients according to the II-GIST Signature in the training and validation cohorts.Table 1Training Cohort (*n* = 130)Internal Validation Cohort (*n* = 194)External Validation Cohort (*n* = 111)nHigh-II-GISTLow-II-GIST*P*nHigh-II-GISTLow-II-GIST*P*nHigh II-GISTLow II-GIST*P*Median age (range)56 (23--77)56 (27--80)0.54256 (26--94)59 (28--76)0.93460 (27--83)61 (44--87)0.070Sex0.2290.7070.803Male7246261207347452916female583127744331664125tumour size0.6070.1540.176≤5cm7543321097039664521\>5cm553421854639452520Primary tumour site0.3690.1520.901Stomach8251311206753754728Non-Stomach482622744925362313Mitotic index0.2020.2510.041≤59660361318249855827\>5341717633429261214NIH criteria0.0550.1650.036High risk542628904842331518Intermediate risk3123832191321165Very Low/Low risk452817724923573918Imatinib therapy0.4780.3620.264Yes18126201010311714No112654717410669805327[^2][^3]

As shown in [Table 1](#tbl0001){ref-type="table"}, the baseline clinicopathological features were similar between the high II-GIST and low II-GIST groups in both the training and internal validation cohorts, while in the external validation cohort, the low II-GIST group seemed to have more advanced disease characteristics. In the training cohort, 77 patients were classified into the high II-GIST group, and 53 were assigned to the low II-GIST group. In the training cohort, the 5-year RFS and OS rates were 94.1 and 94.8%, respectively, in the high II-GIST group and 52.6 and 57.2%, respectively, in the low II-GIST group ([Fig. 3](#fig0003){ref-type="fig"}a). In the internal validation cohort, the RFS (HR=0.110; 95% CI, 0.044--0.274; *P*\<0.001) and OS (HR=0.162; 95% CI, 0.061--0.426; *P*\<0.001) rates in the high II-GIST group were significantly superior to those in the low II-GIST group ([Fig. 3](#fig0003){ref-type="fig"}b). Similarly, the high II-GIST group exhibited higher RFS and OS rates than the low II-GIST group in the external validation cohort ([Fig. 3](#fig0003){ref-type="fig"}c). Multivariable Cox regression analyses demonstrated that II-GIST was an independent prognostic factor for both RFS and OS (Table S4--7).Fig. 3Prognostic impact of the II-GIST signature on RFS and OS. Kaplan-Meier curves of RFS and OS according to the II-GIST signature in the (a) training cohort, (b) internal validation cohort, and (c) external validation cohort. Left panel: RFS; Right panel: OS.Fig. 3

To explore the prognostic discrimination capability of the II-based signature in GIST patients, we performed a time-dependant ROC curve analysis. The AUC values for RFS at 1, 3 and 5 years were 0.81 (95% CI: 0.66--0.96), 0.91 (95% CI: 0.84--0.97) and 0.92 (95% CI: 0.86--0.99), respectively, in the training cohort and 0.87 (95% CI: 0.80--0.95), 0.87 (95% CI: 0.80--0.95) and 0.91(95% CI: 0.83--0.98), respectively, in the internal validation cohort. The AUC values for RFS at 1, 3 and 5 years were 0.82 (95% CI: 0.71--0.92), 0.81 (95% CI: 0.72--0.90) and 0.88 (95% CI: 0.81--0.95), respectively, in the external validation cohort (Fig. S12). ROC curve analysis suggested that the II-GIST signature is potentially more accurate than the NIH risk criteria in terms of prognostic prediction in the internal and external validation cohorts ([Fig. 4](#fig0004){ref-type="fig"}a-d). In addition, the concordance index for the II-GIST signature was 0.842 (95% CI: 0.800--0.885) in the internal cohort and 0.821 (95% CI: 0.757--0.883) in the external cohort and was superior to the concordance index for the NIH criteria, at 0.677 (95% CI 0.600--0.755) in the internal cohort and 0.640 (95% CI 0.526--0.739) in the external cohort (Table S8). The χ^2^ test of proportions demonstrated that the risk in GIST patients is determined mostly by the II-GIST signature (92.3% in the internal validation cohort; 90.5% in the external validation cohort) compared with other features, such as the NIH risk criteria (7.5% in the internal validation cohort; 7.1% in the external validation cohort) and tumour size (0.2% in the internal validation cohort; 2.4% in the external validation cohort) ([Fig. 4](#fig0004){ref-type="fig"}e-f).Fig. 4Prognostic discrimination and relative contribution of the II-GIST signature to the prognosis of GIST patients in the internal and external validation cohorts. Time-dependant ROC curves of II-GIST and NIH risk criteria as predictors of (a) RFS in the internal validation cohort, (b) OS in the internal validation cohort, (c) RFS in the external validation cohort, and (d) OS in the external validation cohort. The relative importance of each risk parameter to survival risk was evaluated using the χ^2^ test of proportions for clinical parameters and clinical parameters plus the II-GIST signature in the (e) internal validation cohort and (f) external validation cohort.Fig. 4

Furthermore, subgroup analyses stratified by clinicopathological features were performed to explore the ability of the II-GIST signature to predict the prognosis of GIST patients in the internal and external validation cohorts. High II-GIST patients showed better OS and RFS outcomes than both low II-GIST patients with moderate/high risk and GIST patients with very low/low risk ([Fig. 5](#fig0005){ref-type="fig"}). When the cohorts were stratified by tumour size, mitotic index and primary tumour location, the II-GIST signature remained an efficient prognostic model (Fig. S13--15).Fig. 5Kaplan-Meier survival analysis of RFS and OS according to the II-GIST signature in the internal and external validation cohorts stratified by NIH risk criteria (moderate/high and very low/low risk). (a) NIH moderate- and high-risk GISTs in the internal validation cohort. (b) NIH very low- and low-risk GISTs in the internal validation cohort. (c) NIH moderate- and high-risk GISTs in the external validation cohort. (d) NIH very low- and low-risk GISTs in the external validation cohort. Left panel: RFS; Right panel: OS.Fig. 5

3.3. II-GIST signature and the benefit of adjuvant imatinib therapy {#sec0014}
-------------------------------------------------------------------

Current clinical practice recommends adjuvant imatinib therapy after surgery for moderate- and high-risk patients with GIST. Thus, the association between the II-GIST signature and the benefit of imatinib treatment was explored amongst moderate- and high-risk groups of patients with GISTs. The benefit of adjuvant imatinib therapy in the high II-GIST group was obvious for both RFS (HR=0.134; 95% CI, 0.025--0.724; *P* = 0.020; *P* = 0.001 for the interaction) and OS (HR=0.050; 95% CI, 0.006--0.440; *P* = 0.007; *P* = 0.006 for the interaction) (Table S9). The Kaplan-Meier survival curves revealed that adjuvant imatinib therapy significantly improved RFS (log-rank *P* = 0.020) and OS (log-rank *P* = 0.007) outcomes in the high II-GIST group, although no obvious differences were detected in the low II-GIST group ([Fig. 6](#fig0006){ref-type="fig"}). Taken together, our data suggest that moderate- and high-risk patients with high II-GIST scores may gain survival benefits from adjuvant imatinib therapy.Fig. 6Association between the II-GIST signature and survival benefit of imatinib therapy in groups of moderate- and high-risk patients with GIST. (a) Kaplan-Meier analysis of RFS (left panel) and OS (right panel) in the high II-GIST group according to imatinib therapy status. (b) Kaplan-Meier analysis of RFS (left panel) and OS (right panel) in the low II-GIST group according to imatinib therapy status.Fig. 6

3.4. PD-1 and PD-L1 in GISTs {#sec0015}
----------------------------

Moreover, we analysed the expression of PD-1 and PD-L1 in GIST patients in the whole cohort (Fig. S16--17). The densities of PD-1^+^cells were similar between the TC and TM (Fig. S3h). The Kaplan-Meier analysis results indicated that high PD-1 expression in TC or TM are not associated with RFS or OS (Fig. S18a-b). PD-L1 expression was found to be positive in only 75 cases (16.3%). No significant difference of survival outcomes was detected between the PD-L1-positive and -negative group, either (Fig. S18c). Seifert et al. suggested that PD-1/PD-L1 blockade enhance T-cell activity and antitumor efficacy of imatinib in murine GISTs [@bib0027]. Then, the correlation between PD-L1 expression and response to imatinib was also evaluated amongst moderate- and high- risk patients. However, the benefit from adjuvant imatinib therapy were not discernable in neither PD-L1 positive nor negative group (Fig. S19).

4. Discussion {#sec0016}
=============

The immune microenvironment has attracted intense attention in the past decade because of the astounding progress in immunotherapy [@bib0028]. TILs, critical components of the immune microenvironment, participate in a complex interplay with their surroundings through which they influence tumour progression, development and metastasis [@bib0029]. During the past several decades, revolutionary progress has occurred in the diagnosis, management and understanding of the molecular mechanisms of GIST, a disease that has been historically consistently misdiagnosed as leiomyoma. However, the role of TILs in GISTs has rarely been addressed. The present study investigated the density and prognostic significance of infiltrating immune cell subpopulations in the TC and TM and proposed an II-based signature to predict prognosis and survival benefits from imatinib therapy.

Over the past decade, TILs have been demonstrated to reflect tumour inflammation and to correlate with prognostic outcomes in tumours [@bib0030], [@bib0031], [@bib0032]. The function of TILs, especially CD8^+^ *T* cells, is to identify unique tumour antigens and block tumour immune escape *via* avoidance of immune recognition \[[@bib0033], [@bib0034]\]. The distribution, density and function of various TIL subsets differ in each spatial location of the tumour [@bib0035]. Some studies have suggested that infiltration of the TC and TM by TILs may exert varied influences on survival outcomes in cancers [@bib0036], [@bib0037], [@bib0038]. Thus, we investigated the distribution and prognostic impact of separate TIL populations and demonstrated that the CD8^+^ and Foxp3^+^ cell densities in the TM are higher in localized tumours than in metastatic tumours. CD45RO^+^ lymphocytes are memory lymphocytes that are indispensable for host defence [@bib0039]. Consistent with a prior report in breast cancer [@bib0040], our study showed that high infiltration levels of CD45RO^+^cells in the TC is associated with small GIST size.

Accumulating literature indicates that TILs in tumours are efficient predictive indicators of prognosis \[[@bib0033], [@bib0041]\]. Higher infiltration levels of CD8^+^ CTLs, important components of tumour-specific cellular adaptive immunity, were associated with better prognosis and pathological complete response to chemotherapy \[[@bib0029], [@bib0042]\]. In addition, CD3^+^ *T* lymphocytes have been associated with prolonged RFS in hepatocellular carcinoma [@bib0012]. NKp46^+^ NK cells, a population of lymphocytes that are part of the innate immune system, were found to correlate significantly with more favourable survival in gastrointestinal malignancies \[[@bib0043], [@bib0044]\]. Tumour-infiltrating CD20^+^ *B* cells (CD20^+^TILs) play a vital role and are correlated with increased survival in ovarian cancer [@bib0045]. In GISTs, accumulating evidence indicates that several haematologic biomarkers, including the platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR), which are precise predictors of prognosis, should include lymphocytes to reflect immunity and inflammation [@bib0046], [@bib0047], [@bib0048]. Regarding TILs, Rusakiewicz et al. reported that NKp46^+^ and CD3^+^ cell infiltrates were associated with lower rates of recurrence and smaller tumour sizes amongst 53 localized GISTs [@bib0016]. In the present study, we investigated the prognostic impact of each TIL population and suggested that high infiltration levels of CD3^+^ TC, CD3^+^ TM, CD8^+^ TC, CD8^+^ TM, CD45RO^+^ TM, NKp46^+^ TM and CD20^+^ TM infiltrations are associated with favourable prognosis. Infiltrating immune cells contribute to immunosurveillance, which eliminates tumour cells and slows immune evasion \[[@bib0049], [@bib0050]\]. Convincing evidence indicates that the presence of tumour immune infiltrates is associated with a good response to treatment in different malignancies \[[@bib0035], [@bib0042], [@bib0051]\]. The abovementioned mechanisms might clarify the association between high infiltration levels of TILs and favourable prognoses of patients with GISTs.

Relapse remains a common clinical occurrence even after complete resection of GISTs [@bib0052], and precise estimation of the recurrence risk is crucial for the management of GISTs [@bib0053]. Currently, the survival outcomes vary amongst GIST patients with identical NIH risk criteria. Due to the inadequate accuracy of the NIH risk criteria, a novel scoring system to evaluate the prognosis of patients with GISTs is urgently needed. The innate immune system performs critical functions in protecting the host from tumours; thus, the focus on immune profiling has increased. TILs have been shown to be positively correlated with the prognosis of patients with various kinds of solid tumours, including GISTs \[[@bib0005], [@bib0006], [@bib0016], [@bib0054]\]. Historically, the role of TILs has been largely investigated in individual TIL populations despite the complexity of immune features, which has led to the discovery of moderate predictive ability of TIL-related markers. Integrating numerous immune infiltrates into a single model has resulted in improved prognostic performance for individualized recurrence risk in several cancer types \[[@bib0005], [@bib0032], [@bib0035]\]. Hence, we developed a novel II-based signature with 4 immune features to independently predict the prognosis of GIST patients. The II-GIST signature is an indicator of bio-immunological characteristics, while the NIH risk criteria are determined mainly according to the following pathologic parameters: tumour size, mitotic index, nuclear pleomorphism, and tumour necrosis [@bib0055]. Our data indicated that the prognostic discrimination capability of the II-GIST signature was significantly superior to that of the NIH risk criteria and exhibited the greatest ability to predict survival risk when it was combined with other clinicopathological features into one model. The II-GIST signature is a comprehensive reflection of the immune environment and is correlated with tumour surveillance and progression and exhibited excellent accuracy for prognostic predictions. When patient cohorts were stratified by other clinicopathological parameters, the II-GIST signature still improved the accuracy of prognostic predictions.

Adjuvant imatinib therapy has been recommended as a first-line postoperative treatment for moderate- and high-risk patients with GISTs harbouring sensitive mutations [@bib0019]. However, the population of moderate- and high-risk patients with GISTs exhibits considerable heterogeneity, which has led to great difficulties in distinguishing patients who could benefit from imatinib treatment. Emerging evidence suggests that TILs are independent predictors of the chemotherapeutic response of solid tumours. Asano et al. demonstrated that a high CD8^+^/Foxp3^+^ TIL ratio correlates with pathological complete response to neoadjuvant chemotherapy in aggressive breast cancer [@bib0051]. Balachandran et al. demonstrated that in GISTs, intratumoural CD3^+^ and CD8^+^ cell infiltration is associated with a favourable response to imatinib [@bib0018]. Rusakiewicz et al. reported that the NKp46/Foxp3 ratio in the TC increased significantly after imatinib treatment [@bib0016]. Thus, we investigated correlations between the novel II-GIST signature and the benefit of adjuvant imatinib treatment in moderate- and high-risk patients with GISTs. Our data suggested that moderate- and high-risk patients with high II-GIST scores might obtain a greater survival benefit from postoperative imatinib therapy compared with those with low II-GIST scores. Balachandran et al. showed that imatinib amplifies a pre-existing immune response in mouse GIST and that CD8^+^T cells are required for its maximal effects [@bib0018]. Borg indicated that imatinib promotes NK cell activation and NK cell-dependant antitumour effects in GISTs [@bib0056]. Taken together, lymphocytes contribute substantially to the antitumour effects of imatinib. The II-GIST signature based on TILs is a comprehensive reflection of the immune status of GIST patients, which may correspondingly predict the effect of imatinib in GISTs. Hence, the II-GIST signature may have the potential to serve as a useful predictor of the response to imatinib and offer better guidance than existing indices for clinical selection of patients who can benefit from imatinib therapy. Considering the limited number of patients received imatinib, the predictive accuracy of the II-GIST signature to imatinib therapy needs to be further validated in larger datasets. Furthermore, Seifert et al. reported that PD-L1 inhibition might augment both the therapeutic effect of imatinib and T cell activity in GISTs [@bib0027]. But in the present study the benefit from adjuvant imatinib therapy are not associated with PD-L1 status (Fig. S19). Consequently, application of the II-GIST signature may contribute to treatment optimization, including that of future immunotherapies.

Some limitations of our study need to be addressed. First, this was a retrospective study, and all enroled patients were of Chinese ethnicity. Second, the sample size seemed to be limited. However, given the comparatively low incidence of GISTs, the current study is one of the largest clinical studies conducted to date. Therefore, the prognostic impact of the II-GIST signature must be validated in further prospective studies to guide clinicians in the identification of patients who require more frequent monitoring and intensive therapy.

5. Conclusion {#sec0017}
=============

In conclusion, the novel II-GIST signature can effectively individualize prognostic predictions for GIST patients and improve the predictive accuracy of common clinicopathological indices. Moreover, the II-GIST signature may have the potential to predict the therapeutic response to imatinib in moderate- and high-risk patients with GISTs. Therefore, the II-GIST signature might guide patient counselling, decision-making regarding individualized adjuvant treatment, and follow-up scheduling.
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Appendix. Supplementary materials {#sec0022}
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Figure S1 Regions of interest (ROIs): tumour centre (TC) and tumour margin (TM). Scale bar: 200 µm.Image, image 1Figure S2 Representative immunohistochemical images of tumour-infiltrating lymphocytes (TILs) in the tumour centre (TC) and tumour margin (TM).Image, image 2Figure S3 Distribution of individual tumour-infiltrating lymphocytes (TILs) in the tumour centre (TC) and tumour margin (TM) of gastrointestinal stromal tumours (GISTs). (a) CD3^+^, (b) CD8^+^, (c) CD45RO^+^, (d) Foxp3^+^, (e) CD4^+^, (f) NKp46^+^, (g) CD20^+^ and (h) PD-1^+^cell counts in the TC and TM across all patients analysed (*n* = 435).Image, image 3Figure S4 Correlation between the disease extent and the absolute counts of individual TILs in the TC and TM. (a) CD3^+^, (b) CD8^+^, (c) CD45RO^+^, (d) Foxp3^+^, (e) CD4^+^, (f) NKp46^+^ and (g) CD20^+^ cells were quantified in the TC and TM according to disease extent (localized vs*.* metastatic). TC: tumour centre; TM: tumour margin.Image, image 4Figure S5 Correlation between tumour size and absolute counts of individual TILs in the TC and TM of GISTs. (a) CD3^+^, (b) CD8^+^, (c) CD45RO^+^, (d) Foxp3^+^, (e) CD4^+^, (f) NKp46^+^ and (g) CD20^+^ cells were quantified in the TC and TM according to tumour size (≤5 vs*.* \>5 cm).Image, image 5Figure S6 Correlation between the primary tumour site and the absolute counts of individual TILs in the TC and TM. (a) CD3^+^, (b) CD8^+^, (c) CD45RO^+^, (d) Foxp3^+^, (e) CD4^+^, (f) NKp46^+^ and (g) CD20^+^ cells were quantified in the TC and TM according to the primary tumour site (stomach vs*.* non-stomach).Image, image 6Figure S7 Kaplan-Meier analysis of RFS according to individual TILs in the TM. (a) CD3^+^ TM. (b) CD8^+^TM. (c) CD45RO^+^ TM, (d) Foxp3^+^ TM. (e) CD4^+^ TM. (f) NKp46^+^ TM. (g) CD20^+^ TM.Image, image 7Figure S8 Kaplan-Meier analysis of OS according to individual TILs in the TC. (a) CD3^+^ TC. (b) CD8^+^ TC. (c) CD45RO^+^ TC, (d) Foxp3^+^ TC. (e) CD4^+^ TC. (f) NKp46^+^ TC. (g) CD20^+^ TC.Image, image 8Figure S9 Kaplan-Meier analysis of OS according to individual TILs in the TM. (a) CD3^+^ TM. (b) CD8^+^ TM. (c) CD45RO^+^ TM, (d) Foxp3^+^ TM. (e) CD4^+^ TM. (f) NKp46^+^TM. (g) CD20^+^ TM.Image, image 9Figure S10 The predictive ability of individual TILs for RFS and OS was assessed by time-dependant ROC curve analysis at 5 years (a) amongst patients from the First Affiliated Hospital of Sun Yat-sen University (b) amongst patients from the Second Affiliated Hospital of Guangzhou University of Chinese Medicine. Left panel: RFS; Right panel: OS; AUC: area under the ROC curve.Image, image 10Figure S11 A correlation matrix of 14 immune features followed by unsupervised hierarchical clustering is represented from *R*=−1 negative correlation (blue) to *R* = 1 positive correlation (red). Values of *p*\<0.05 were indicated with asterisks (\*\**p* ≤ 0.01) (Spearman\'s test).Image, image 11Figure S12 The predictive ability of the II-GIST signature for RFS and OS was assessed by time-dependant ROC curve analysis in the (a) training cohort, (b) internal validation cohort, and (c) external validation cohort. Left panel: RFS; Right panel: OS; AUC: area under the ROC curve.Image, image 12Figure S13 Kaplan-Meier survival analysis of RFS and OS according to the II-GIST signature in the internal and external validation cohorts stratified by the tumour size (\>5 and ≤5 cm). (a) Tumour size \>5 cm in the internal validation cohort. (b) Tumour size ≤5 cm in the internal validation cohort. (c) Tumour size \>5 cm in the external validation cohort. (d) Tumour size ≤5 cm in the external validation cohort. Left panel: RFS; Right panel: OS.Image, image 13Figure S14 Kaplan-Meier survival analysis of RFS and OS according to the II-GIST signature in the internal and external validation cohorts stratified by mitotic index (\>5 and ≤5). (a) GISTs with mitotic index \>5 in the internal validation cohort. (b) GISTs with mitotic index ≤5 in the internal validation cohort. (c) GISTs with mitotic index \>5 in the external validation cohort. (d) GISTs with mitotic index ≤5 in the external validation cohort. Left panel: RFS; Right panel: OS. The mitotic index was determined as the number of mitoses per 50 high-power fields (HPFs).Image, image 14Figure S15 Kaplan-Meier survival analysis of RFS and OS according to the II-GIST signature in the internal and external validation cohorts stratified by primary tumour site (stomach and non-stomach). (a) Stomach GISTs in the internal validation cohort. (b) Non-stomach GISTs in the internal validation cohort. (c) Stomach GISTs in the external validation cohort. (d) Non-stomach GISTs in the external validation cohort. Left panel: RFS; Right panel: OS.Image, image 15Figure S16 Representative immunohistochemical images of PD-1 in the TC and TM.Image, image 16Figure S17 Representative immunohistochemical images of PD-L1 in GISTs.Image, image 17Figure S18 Prognostic impact of PD-1^+^ TILs and PD-L1 on RFS and OS. Kaplan-Meier curves of RFS and OS according to (a) PD-1^+^TC, (b) PD-1^+^ TM, and (c) PD-L1. Left panel: RFS; Right panel: OS.Image, image 18Figure S19 Association between the PD-L1 expression and survival benefit of imatinib therapy in groups of moderate- and high-risk patients with GIST. (a) Kaplan-Meier analysis of RFS (left panel) and OS (right panel) in the PD-L1-positive group according to imatinib therapy status. (b) Kaplan-Meier analysis of RFS (left panel) and OS (right panel) in the PD-L1-negative group according to imatinib therapy status.Image, image 19Image, application 20
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